Stock Analiz

Marker Therapeutics, Inc. MRKR

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.87Market cap $15M
Open the interactive analysis →

Marker Therapeutics, Inc. (MRKR) is a healthcare company listed in the US with a market value of about $15M. In fiscal year 2025 it had revenue of $4M and net income of -$12M, a net margin of -343.0%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 48% a year, a 5-year average ROIC of -64%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 82% below the current price.

About Marker Therapeutics

Marker Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $183064 in 2017 to $4M in 2025, growth of about 44.8% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 83% over three years (dilution for shareholders). It spends 333% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S4.1
P/B1.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−82%

Growth and quality

Revenue growth (1 yr)-46.2%
Revenue growth (5 yrs, per year)48.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-401.6%
ROIC (5-yr avg.)-63.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$4M$7M$3M$4M$0$500000$213194$205994$183064—
Net income-$12M-$11M-$8M-$30M-$42M-$29M-$21M-$148M-$11M-$2M
Free cash flow——————-$19M-$15M-$8M—
EPS (diluted)$-0.79$-1.19$-0.94$-3.58$-5.47$-6.10$-4.70$-77.50$-11.60$-7.20
Net margin-343.0%-162.8%-248.8%-851.9%—-5741.2%-10050.9%-71826.3%-5999.1%—
ROIC-76.6%-47.3%-82.0%-57.4%-55.8%-57.6%-39.9%-195.1%-247.6%-108.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Marker Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 82% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Marker Therapeutics pay a dividend?

Not currently.

Is Marker Therapeutics a good stock to buy?

We do not give buy or sell advice. Marker Therapeutics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.